The following are active clinical trials which you can discuss with your healthcare team or call (631) 638-0846.
Study: NSABP B-49 – A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Principal Investigator: Janice Lu, MD
Department:
Start Date: April 2011
End Date:
Study: NSABP FB-7: A Phase II randomized clinical trial evaluating Neoadjuvant therapy regimens with weekly Paclitaxel and Neratinib or Trastuzumab followed by Doxorubicin and Cyclophosphamide with post-operative Trastuzumab in women with locally advanced HER2 positive breast cancer
Principal Investigator: Janice Lu, MD
Department:
Start Date: On Hold For Accrual
End Date:
Study: NSABP B-47: A randomized Phase III Trial of adjuvant therapy comparing chemotherapy alone (six cycles of Docetaxel plus Cyclophosphamide followed by weekly Paclitaxel) to chemotherapy plus Trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer
Principal Investigator: A. Kudelka, MD
Department:
Start Date: 5/27/11
End Date:
Study: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiaton Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma in Situa Resected by NSAPB B-43
Principal Investigator: Jules Cohen, MD
Department:
Start Date:
End Date:
Study: A Phase II Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-2 Positive Nodes, Homrone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less - S1007
Principal Investigator: Andrzej Kudelka, MD
Department:
Start Date:
End Date: